What does it measure?
This test measures a marker related to the MUC1 protein found on cell surfaces. Some breast cancers release more of it into the blood. A specialist may follow the value over time when it is informative for an already diagnosed cancer. [1]
Before the test
- Sample
- A blood sample from a vein.
- Supplements
- Tell the laboratory about biotin-containing products and follow its assay-specific instructions.
What can the result mean?
A rising value can prompt further assessment, but does not prove cancer progression by itself. A falling value may support a treatment response when the wider assessment agrees. Some cancers do not raise CA 15-3, and noncancerous conditions can also affect it. [1] [4]
When is it useful, and how is it read?
CA 15-3 may add information when monitoring treatment for metastatic breast cancer, alongside symptoms, examination, and imaging. It is not recommended for routine surveillance after treatment intended to cure breast cancer when there are no symptoms or concerning examination findings. The oncology team decides whether the marker is useful; it must not determine treatment changes alone. [1] [3] [4] [5]
What can affect it?
Treatment timing, prior values, other health conditions, and assay method all matter. Biotin or other assay interferences can affect some methods; follow the laboratory’s instructions about supplements. Changing laboratories can make a trend harder to interpret. [1]
Myth: «A rise by itself means the treatment has stopped working»
A change in this marker needs comparison with symptoms, examination, imaging, and treatment timing. It should not be the only reason to decide that a cancer has progressed or to change treatment. [1]
Questions you might have
Does CA 15-3 replace breast screening?
No. It can support selected monitoring during treatment of metastatic breast cancer. It is not a general screening test or a routine surveillance test after curative treatment when there are no symptoms or concerning examination findings. [3] [5]
Does a rise by itself prove that treatment has failed?
No. The oncology team reads the trend alongside symptoms, examination, and imaging. [1]
What comes next?
Use the result with the treating specialist’s examination and imaging plan. CA 15-3 does not replace breast screening, imaging, or biopsy and should not be used to reassure healthy people that they do not have cancer. [1] [2]
Has CA 15-3 been a useful marker in my case, and does any change agree with the clinical assessment?
The reference interval and units on your report are part of understanding your result. Understand units, reference intervals, and treatment targets.
Sources & references
Medical references & original research
- Mayo Clinic Laboratories — Cancer Antigen 15-3, Serum
- National Cancer Institute — Tumor Markers
- ASCO — Biomarkers for Systemic Therapy in Metastatic Breast Cancer: Guideline Update (2022)
- University Hospitals of North Midlands — Cancer antigen 15.3
- ASCO — Breast Cancer Follow-Up and Surveillance After Primary Treatment: Guideline Update (2026)
Books we consulted
References that informed our explanations of the test and its context.
- Pagana KD, Pagana TJ, Pagana TN. Mosby’s Diagnostic and Laboratory Test Reference. 14th ed. Elsevier; 2019.
Practical-section sources accessed: .
For general health education. Interpreting your result and deciding on tests or treatment requires your health context and a qualified clinician.
